Issue Information
23 February 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial
Graham R. Foster, Kosh Agarwal, Matthew E. Cramp, Sulleman Moreea, Stephen Barclay, Jane Collier, Ashley S. Brown, Stephen D. Ryder, Andrew Ustianowski, Daniel M. Forton, Ray Fox, Fiona Gordon, William M. Rosenberg, David J. Mutimer, Jiejun Du, Christopher L. Gilbert, Ernest Asante‐Appiah, Janice Wahl, Michael N. Robertson, Eliav Barr, Barbara Haber – 23 February 2018 – Many direct‐acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT) 3 infection and cirrhosis.
Issue Information
23 February 2018
Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver
Ruben Bill, Matteo Montani, Benedikt Blum, Jean‐François Dufour, Robert Escher, Michael Bühlmann – 23 February 2018
The diminishing role of liver biopsy in living donor liver transplantation
James F. Trotter – 21 February 2018
Introducing Ronald J. Sokol, M.D.—our 2018 AASLD president
Cara L. Mack – 21 February 2018
Updated Hepatitis B Guidance: Implications for liver transplant patients
Elizabeth C. Verna – 21 February 2018
Uploading cellular batteries: Caring for mitochondria is key
Philipp Dutkowski, Pierre‐Alain Clavien – 20 February 2018
New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome
Wei Zhang, Debapriya De, Kahee A. Mohammed, Satish Munigala, Guilan Chen, Jin‐Ping Lai, Bruce R. Bacon – 20 February 2018 – Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are two major immune‐mediated chronic liver diseases. Overlap syndrome (OS) is diagnosed if patients have features of both AIH and PBC; however, there is no consensus on the definition or diagnostic criteria for OS. Here, we report a new scoring classification for OS and evaluate its usefulness.
Long‐term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy
Daniel Zamora‐Valdes, Kymberly D. Watt, Todd A. Kellogg, John J. Poterucha, Sara R. Di Cecco, Nicki M. Francisco‐Ziller, Timucin Taner, Charles B. Rosen, Julie K. Heimbach – 19 February 2018 – Obesity is increasingly common before and after liver transplantation (LT), yet optimal management remains unclear. The aim of this study was to analyze the long‐term outcomes for obese patients undergoing LT, including a noninvasive weight loss program and combined LT and sleeve gastrectomy (SG). Since 2006, all patients referred for LT with a body mass index (BMI) ≥35 kg/m2 were enrolled.